
Professor Kamlesh Khunti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8303084/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
2	Type 2 diabetes. Lancet, The, 2017, 389, 2239-2251.	6.3	1,691
3	Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia, 2012, 55, 2895-2905.	2.9	1,371
4	The prevalence of co-morbid depression in adults with TypeÂ2 diabetes: a systematic review and meta-analysis. Diabetic Medicine, 2006, 23, 1165-1173.	1.2	1,002
5	Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ: British Medical Journal, 2007, 334, 299.	2.4	930
6	Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes and Endocrinology,the, 2020, 8, 813-822.	5.5	733
7	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2020, 98, S1-S115.	2.6	692
8	Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 546-550.	5.5	680
9	Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 823-833.	5.5	677
10	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation, 2017, 136, 249-259.	1.6	672
11	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	13.9	641
12	New-Onset Diabetes in Covid-19. New England Journal of Medicine, 2020, 383, 789-790.	13.9	624
13	Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ: British Medical Journal, 2008, 336, 491-495.	2.4	617
14	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	13.9	526
15	Clinical Inertia in People With Type 2 Diabetes. Diabetes Care, 2013, 36, 3411-3417.	4.3	508
16	Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ, The, 2021, 372, n693.	3.0	494
17	Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ, The, 2020, 369, m1361.	3.0	485
18	Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ, The, 2020, 371, m3731.	3.0	471

#	Article	IF	CITATIONS
19	Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100630.	3.2	454
20	Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations. Diabetes Care, 2014, 37, 922-933.	4.3	448
21	The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine, 2020, 23, 100404.	3.2	442
22	Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy, 2018, 35, 1763-1774.	1.3	424
23	Is ethnicity linked to incidence or outcomes of covid-19?. BMJ, The, 2020, 369, m1548.	3.0	408
24	Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet, The, 2011, 378, 156-167.	6.3	406
25	Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 965-967.	1.8	390
26	Ethnicity and COVID-19: an urgent public health research priority. Lancet, The, 2020, 395, 1421-1422.	6.3	388
27	The effects of highâ€intensity interval training on glucose regulation and insulin resistance: a metaâ€analysis. Obesity Reviews, 2015, 16, 942-961.	3.1	387
28	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018, 71, 2628-2639.	1.2	370
29	Efficacy and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes mellitus: systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2016, 18, 783-794.	2.2	355
30	Prevalence of coâ€morbidities and their association with mortality in patients with <scp>COVID</scp> â€19: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1915-1924.	2.2	320
31	Efficacy and safety of glucagonâ€like peptideâ€1 receptor agonists in type 2 diabetes: <scp>A</scp> systematic review and mixedâ€treatment comparison analysis. Diabetes, Obesity and Metabolism, 2017, 19, 524-536.	2.2	305
32	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	13.9	299
33	Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes and Endocrinology,the, 2019, 7, 385-396.	5.5	298
34	The prevalence of diabetesâ€specific emotional distress in people with Type 2 diabetes: a systematic review and metaâ€analysis. Diabetic Medicine, 2017, 34, 1508-1520.	1.2	285
35	Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 2015, 38, 316-322.	4.3	276
36	Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ, The, 2012, 344, e2333-e2333.	3.0	268

#	Article	IF	CITATIONS
37	Associations of objectively measured sedentary behaviour and physical activity with markers of cardiometabolic health. Diabetologia, 2013, 56, 1012-1020.	2.9	268
38	Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2144-2153.	15.2	249
39	Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism, 2018, 20, 427-437.	2.2	247
40	Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ: British Medical Journal, 2008, 336, 1180-1185.	2.4	239
41	Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes and Endocrinology,the, 2018, 6, 130-142.	5.5	233
42	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. Diabetes Care, 2016, 39, 130-138.	4.3	229
43	Realâ€world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabetic Medicine, 2013, 30, 512-524.	1.2	228
44	Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, The, 2021, 374, n1931.	3.0	217
45	Quality of Care of People With Type 2 Diabetes in Eight European Countries. Diabetes Care, 2013, 36, 2628-2638.	4.3	215
46	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 27-35.	5.5	215
47	Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care, 2015, 38, 1449-1455.	4.3	214
48	Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, Obesity and Metabolism, 2016, 18, 401-409.	2.2	207
49	Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 100.	2.7	206
50	Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulinâ€ŧreated type 1 and type 2 diabetes: the global <scp>HAT</scp> study. Diabetes, Obesity and Metabolism, 2016, 18, 907-915.	2.2	203
51	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International, 2020, 98, 839-848.	2.6	193
52	Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia, 2013, 56, 1489-1493.	2.9	191
53	Type 2 diabetes and cardiovascular disease in South Asians. Primary Care Diabetes, 2011, 5, 45-56.	0.9	177
54	Epidemiology and determinants of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 966-978.	5.5	171

#	Article	IF	CITATIONS
55	Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Primary Care Diabetes, 2017, 11, 3-12.	0.9	170
56	Effectiveness of a Pragmatic Education Program Designed to Promote Walking Activity in Individuals With Impaired Glucose Tolerance. Diabetes Care, 2009, 32, 1404-1410.	4.3	169
57	Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ: British Medical Journal, 2010, 341, c4093-c4093.	2.4	168
58	Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study. European Heart Journal, 2017, 38, 3232-3240.	1.0	168
59	Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes, Obesity and Metabolism, 2018, 20, 488-496.	2.2	167
60	Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open, 2017, 7, e016358.	0.8	165
61	COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care, 2021, 44, 2645-2655.	4.3	164
62	Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE, 2015, 10, e0126427.	1.1	161
63	Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20â€year retrospective cohort study. Clinical Endocrinology, 2013, 78, 926-934.	1.2	156
64	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology,the, 2021, 9, 786-798.	5.5	155
65	The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabetic Medicine, 2010, 27, 887-895.	1.2	151
66	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovascular Diabetology, 2018, 17, 150.	2.7	149
67	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care, 2020, 43, 1695-1703.	4.3	147
68	Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis. Diabetes Care, 2017, 40, 1588-1596.	4.3	143
69	Healthy lifestyle and life expectancy in people with multimorbidity in the UK Biobank: A longitudinal cohort study. PLoS Medicine, 2020, 17, e1003332.	3.9	143
70	Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes and Endocrinology,the, 2021, 9, 293-303.	5.5	140
71	Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study. EClinicalMedicine, 2020, 25, 100466.	3.2	129
72	The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia, 2007, 50, 1116-1126.	2.9	123

#	Article	IF	CITATIONS
73	Diabetes education and self-management for ongoing and newly diagnosed (DESMOND): Process modelling of pilot study. Patient Education and Counseling, 2006, 64, 369-377.	1.0	122
74	Ethnic Disparities in Diabetes Management and Pay-for-Performance in the UK: The Wandsworth Prospective Diabetes Study. PLoS Medicine, 2007, 4, e191.	3.9	117
75	Long terms trends of multimorbidity and association with physical activity in older English population. International Journal of Behavioral Nutrition and Physical Activity, 2016, 13, 8.	2.0	116
76	Early Outcomes From the English National Health Service Diabetes Prevention Programme. Diabetes Care, 2020, 43, 152-160.	4.3	116
77	Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study. Lancet Regional Health - Europe, The, 2021, 9, 100180.	3.0	116
78	Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies. Lancet Public Health, The, 2021, 6, e587-e597.	4.7	116
79	Accelerometer-assessed Physical Activity in Epidemiology. Medicine and Science in Sports and Exercise, 2018, 50, 257-265.	0.2	115
80	Beyond Cut Points: Accelerometer Metrics that Capture the Physical Activity Profile. Medicine and Science in Sports and Exercise, 2018, 50, 1323-1332.	0.2	114
81	Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2018, 137, 137-148.	1.1	114
82	SGLT-2 Inhibitors and Cardiovascular Risk. Journal of the American College of Cardiology, 2018, 71, 2497-2506.	1.2	113
83	A method of identifying and correcting miscoding, misclassification and misdiagnosis in diabetes: a pilot and validation study of routinely collected data. Diabetic Medicine, 2010, 27, 203-209.	1.2	110
84	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	2.0	110
85	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. European Journal of Preventive Cardiology, 2017, 24, 1637-1645.	0.8	109
86	Patterns of Multimorbidity in Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. Mayo Clinic Proceedings, 2018, 93, 857-866.	1.4	105
87	Cardiovascular events and allâ€cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: <scp>A B</scp> ayesian metaâ€analysis of survival data. Diabetes, Obesity and Metabolism, 2017, 19, 329-335.	2.2	104
88	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye, 2020, 34, 1-51.	1.1	104
89	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in <scp>E</scp> urope and the <scp>USA</scp> . Diabetes, Obesity and Metabolism, 2017, 19, 1155-1164.	2.2	100
90	Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881984469.	1.4	100

#	Article	IF	CITATIONS
91	Study of Once Daily Levemir (SOLVEâ,,¢): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes, Obesity and Metabolism, 2012, 14, 654-661.	2.2	99
92	First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. Diabetes Care, 2018, 41, 2396-2403.	4.3	99
93	Raw Accelerometer Data Analysis with GGIR R-package. Medicine and Science in Sports and Exercise, 2016, 48, 1935-1941.	0.2	97
94	Intensity Thresholds on Raw Acceleration Data: Euclidean Norm Minus One (ENMO) and Mean Amplitude Deviation (MAD) Approaches. PLoS ONE, 2016, 11, e0164045.	1.1	96
95	Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care, 2020, 43, 2313-2322.	4.3	95
96	Defining Obesity Cut-Off Points for Migrant South Asians. PLoS ONE, 2011, 6, e26464.	1.1	95
97	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. European Journal of Preventive Cardiology, 2021, 28, 1599-1609.	0.8	93
98	Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematology,the, 2017, 4, e83-e93.	2.2	91
99	Quality of diabetes care in the UK: comparison of published qualityâ€ofâ€care reports with results of the Quality and Outcomes Framework for Diabetes. Diabetic Medicine, 2007, 24, 1436-1441.	1.2	90
100	The association between neighbourhood greenspace and type 2 diabetes in a large cross-sectional study. BMJ Open, 2014, 4, e006076.	0.8	89
101	The impact of obesity on severe disease and mortality in people with SARS oVâ€2: A systematic review and metaâ€analysis. Endocrinology, Diabetes and Metabolism, 2021, 4, e00176.	1.0	87
102	Nonlinear association of BMI with all-cause and cardiovascular mortality in type 2 diabetes mellitus: a systematic review and meta-analysis of 414,587 participants in prospective studies. Diabetologia, 2017, 60, 240-248.	2.9	86
103	Miscoding, misclassification and misdiagnosis of diabetes in primary care. Diabetic Medicine, 2012, 29, 181-189.	1.2	83
104	A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. Preventive Medicine, 2016, 84, 48-56.	1.6	83
105	Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes and Endocrinology,the, 2018, 6, 821-832.	5.5	83
106	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health, The, 2019, 4, e406-e420.	4.7	82
107	Associations of mutually exclusive categories of physical activity and sedentary time with markers of cardiometabolic health in English adults: a cross-sectional analysis of the Health Survey for England. BMC Public Health, 2015, 16, 25.	1.2	81
108	Accuracy of Posture Allocation Algorithms for Thigh- and Waist-Worn Accelerometers. Medicine and Science in Sports and Exercise, 2016, 48, 1085-1090.	0.2	80

#	Article	IF	CITATIONS
109	Clinical inertia in management of T2DM. Primary Care Diabetes, 2010, 4, 203-207.	0.9	79
110	Clinical inertia—Time to reappraise the terminology?. Primary Care Diabetes, 2017, 11, 105-106.	0.9	79
111	Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. British Journal of Psychiatry, 2019, 214, 63-73.	1.7	77
112	Impact of weight gain on outcomes in type 2 diabetes. Current Medical Research and Opinion, 2011, 27, 1431-1438.	0.9	76
113	Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. Diabetic Medicine, 2015, 32, 407-413.	1.2	74
114	Rationale and design of the ADDITION-Leicester study, a systematic screening programme and Randomised Controlled Trial of multi-factorial cardiovascular risk intervention in people with Type 2 Diabetes Mellitus detected by screening. Trials, 2010, 11, 16.	0.7	71
115	Guidelines for managing diabetes in Ramadan. Diabetic Medicine, 2016, 33, 1315-1329.	1.2	70
116	Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments. Annals of Internal Medicine, 2016, 164, 102.	2.0	70
117	Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners. European Journal of Heart Failure, 2002, 4, 771-777.	2.9	69
118	Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?. Diabetes, Obesity and Metabolism, 2018, 20, 1337-1341.	2.2	69
119	Obesity and risk of COVID-19: analysis of UK biobank. Primary Care Diabetes, 2020, 14, 566-567.	0.9	69
120	Ethnicity, household composition and COVID-19 mortality: a national linked data study. Journal of the Royal Society of Medicine, 2021, 114, 182-211.	1.1	69
121	Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. Diabetologia, 2012, 55, 959-966.	2.9	68
122	Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Network Open, 2018, 1, e185554.	2.8	67
123	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes and Endocrinology,the, 2020, 8, 606-615.	5.5	67
124	Walking Away from Type 2 diabetes: a cluster randomized controlled trial. Diabetic Medicine, 2017, 34, 698-707.	1.2	66
125	Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. European Journal of Epidemiology, 2021, 36, 605-617.	2.5	66
126	Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart, 2007, 93, 1398-1405.	1.2	65

#	ARTICLE	IF	CITATIONS
127	Rates of myocardial infarction and stroke in patients initiating treatment with <scp>SGLT</scp> 2â€inhibitors versus other glucoseâ€lowering agents in realâ€world clinical practice: <scp>R</scp> esults from the <scp>CVDâ€REAL</scp> study. Diabetes, Obesity and Metabolism, 2018, 20, 1983-1987.	2.2	65
128	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: <scp>F</scp> actors predicting intensification of treatment. Diabetes, Obesity and Metabolism, 2018, 20, 103-112.	2.2	65
129	Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action. Trials, 2021, 22, 880.	0.7	65
130	Associations Between Sedentary Behaviors and Cognitive Function: Cross-Sectional and Prospective Findings From the UK Biobank. American Journal of Epidemiology, 2018, 187, 441-454.	1.6	64
131	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. Diabetes Research and Clinical Practice, 2019, 151, 20-32.	1.1	63
132	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Primary Care Diabetes, 2018, 12, 265-283.	0.9	62
133	Causality between nonâ€alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A metaâ€analysis with bias analysis. Liver International, 2019, 39, 557-567.	1.9	62
134	Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. Diabetes Research and Clinical Practice, 2020, 165, 108266.	1.1	62
135	Levels of physical activity and relationship with markers of diabetes and cardiovascular disease risk in 5474 white European and South Asian adults screened for type 2 diabetes. Preventive Medicine, 2010, 51, 290-294.	1.6	61
136	Who looks after people with diabetes: Primary or secondary care?. Journal of the Royal Society of Medicine, 2000, 93, 183-186.	1.1	60
137	A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study. Diabetes Research and Clinical Practice, 2012, 97, 505-513.	1.1	60
138	Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. British Journal of General Practice, 2016, 66, e315-e322.	0.7	60
139	Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet Diabetes and Endocrinology,the, 2016, 4, 677-685.	5.5	60
140	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. The Lancet Gastroenterology and Hepatology, 2021, 6, 743-753.	3.7	60
141	Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Journal of Public Health, 2022, 44, 234-245.	1.0	60
142	Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. European Journal of Epidemiology, 2017, 32, 657-667.	2.5	59
143	Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms. European Heart Journal Cardiovascular Imaging, 2014, 15, 1263-1269.	0.5	58
144	Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia, 2020, 63, 698-710.	2.9	58

#	Article	IF	CITATIONS
145	Objectively measured sedentary time and associations with insulin sensitivity: Importance of reallocating sedentary time to physical activity. Preventive Medicine, 2015, 76, 79-83.	1.6	57
146	Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e270.	2.1	57
147	Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 571-580.	5.5	57
148	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. Diabetes Care, 2014, 37, 2015-2023.	4.3	56
149	Comorbid depression and risk of cardiac events and cardiac mortality in people with diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2019, 156, 107816.	1.1	56
150	Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes. Diabetes, Obesity and Metabolism, 2019, 21, 1668-1679.	2.2	56
151	The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Research and Clinical Practice, 2010, 90, 100-108.	1.1	55
152	Sedentary Sphere. Medicine and Science in Sports and Exercise, 2016, 48, 748-754.	0.2	55
153	Impact of the National Health Service Health Check on cardiovascular disease risk: a difference-in-differences matching analysis. Cmaj, 2016, 188, E228-E238.	0.9	54
154	Effects of blood pressure and lipid lowering on cognition. Neurology, 2019, 92, e1435-e1446.	1.5	54
155	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129.	1.1	53
156	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Annals of Internal Medicine, 2020, 172, 541.	2.0	53
157	Features of primary care associated with variations in process and outcome of care of people with diabetes. British Journal of General Practice, 2001, 51, 356-60.	0.7	53
158	Diabetes and Ramadan: Practical guidelines 2021. Diabetes Research and Clinical Practice, 2022, 185, 109185.	1.1	53
159	â€~Educator talk' and patient change: some insights from the DESMOND (Diabetes Education and Self) Tj ET 25, 1117-1120.	Qq1 1 0.7 1.2	784314 rgBT 52
160	Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. European Heart Journal, 2017, 38, 1608-1612.	1.0	52
161	Effects of Low-Energy Diet or Exercise on Cardiovascular Function in Working-Age Adults With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded End Point Trial. Diabetes Care, 2020, 43, 1300-1310.	4.3	52
162	Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. Postgraduate Medical Journal, 2017, 93, 289-294.	0.9	51

Professor Kamlesh Khunti

#	Article	IF	CITATIONS
163	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	1.3	51
164	Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001061.	1.2	50
165	Clinical management of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 979-991.	5.5	49
166	Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Clinical Diabetes, 2020, 38, 371-381.	1.2	49
167	Walking away from type 2 diabetes: trial protocol of a cluster randomised controlled trial evaluating a structured education programme in those at high risk of developing type 2 diabetes. BMC Family Practice, 2012, 13, 46.	2.9	48
168	Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population. JACC: Heart Failure, 2018, 6, 18-26.	1.9	48
169	COVID-19 and ethnicity: A novel pathophysiological role for inflammation. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1043-1051.	1.8	48
170	Covid-19 and ethnic minorities: an urgent agenda for overdue action. BMJ, The, 2020, 369, m2503.	3.0	48
171	Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. British Journal of Diabetes and Vascular Disease, 2015, 15, 65.	0.6	48
172	SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study. PLoS Medicine, 2021, 18, e1003823.	3.9	48
173	Older people with Type 2 diabetes, including those with chronic kidney disease or dementia, are commonly overtreated with sulfonylurea or insulin therapies. Diabetic Medicine, 2017, 34, 1219-1227.	1.2	47
174	Barriers and Facilitators to Healthy Lifestyle Changes in Minority Ethnic Populations in the UK: a Narrative Review. Journal of Racial and Ethnic Health Disparities, 2017, 4, 1107-1119.	1.8	47
175	Effectiveness of the â€~Girls Active' school-based physical activity programme: A cluster randomised controlled trial. International Journal of Behavioral Nutrition and Physical Activity, 2018, 15, 40.	2.0	47
176	COVID-19 mortality: a complex interplay of sex, gender and ethnicity. European Journal of Public Health, 2020, 30, 847-848.	0.1	47
177	Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2137-2154.	2.2	47
178	Impact of Information Technology–Based Interventions for Type 2 Diabetes Mellitus on Glycemic Control: A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e310.	2.1	47
179	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. Journal of Diabetes and Its Complications, 2017, 31, 1188-1196.	1.2	46
180	Associations of Physical Behaviours and Behavioural Reallocations with Markers of Metabolic Health: A Compositional Data Analysis. International Journal of Environmental Research and Public Health, 2018, 15, 2280.	1.2	46

#	Article	IF	CITATIONS
181	Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovascular Diabetology, 2019, 18, 70.	2.7	46
182	Efficacy and tolerability of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1035-1046.	2.2	46
183	The safety and efficacy of adding onceâ€daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes, Obesity and Metabolism, 2012, 14, 1129-1136.	2.2	45
184	Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. Diabetes Research and Clinical Practice, 2014, 104, 281-287.	1.1	45
185	Comparison of body mass index at diagnosis of diabetes in a multiâ€ethnic population: <scp>A</scp> caseâ€control study with matched nonâ€diabetic controls. Diabetes, Obesity and Metabolism, 2017, 19, 1014-1023.	2.2	45
186	Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes and Endocrinology,the, 2021, 9, 671-680.	5.5	45
187	The Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2 years?. Diabetic Medicine, 2011, 28, 1268-1271.	1.2	44
188	Coverage of a national cardiovascular risk assessment and management programme (NHS Health) Tj ETQq0 0 0	rgBT/Ove 1.6	rloçk 10 Tf 5C
189	Aspirin for primary prevention of cardiovascular and allâ€cause mortality events in diabetes: updated metaâ€analysis of randomized controlled trials. Diabetic Medicine, 2017, 34, 316-327.	1.2	44
190	Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology,the, 2018, 6, 992-1002.	5.5	43
191	Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank. International Journal of Obesity, 2021, 45, 1155-1159.	1.6	43
192	Comparative Relevance of Physical Fitness and Adiposity on Life Expectancy. Mayo Clinic Proceedings, 2019, 94, 985-994.	1.4	42
193	Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. European Journal of Heart Failure, 2004, 6, 571-576.	2.9	41
194	Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: The Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research and Clinical Practice, 2011, 93, 328-336.	1.1	41
195	Risk assessment tools for detecting those with pre-diabetes: A systematic review. Diabetes Research and Clinical Practice, 2014, 105, 1-13.	1.1	41
196	Is the number of fast-food outlets in the neighbourhood related to screen-detected type 2 diabetes mellitus and associated risk factors?. Public Health Nutrition, 2015, 18, 1698-1705.	1.1	41
197	Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K BMC Infectious Diseases, 2021, 21, 908.	1.3	41
198	Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. Diabetes Care, 2021, 44, 2790-2811.	4.3	41

#	Article	IF	CITATIONS
199	Physical activity and sedentary behaviours of South Asian and white European children in inner city secondary schools in the UK. Family Practice, 2007, 24, 237-244.	0.8	40
200	Sleep duration, obesity and insulin resistance in a multi-ethnic UK population at high risk of diabetes. Diabetes Research and Clinical Practice, 2018, 139, 195-202.	1.1	40
201	Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2169-2178.	2.2	40
202	Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes. Diabetes Care, 2018, 41, 2096-2104.	4.3	40
203	Multimorbidity and lifestyle factors among adults with intellectual disabilities: a crossâ€sectional analysis of a UK cohort. Journal of Intellectual Disability Research, 2019, 63, 255-265.	1.2	40
204	Enhancing the value of accelerometer-assessed physical activity: meaningful visual comparisons of data-driven translational accelerometer metrics. Sports Medicine - Open, 2019, 5, 47.	1.3	40
205	Waist circumference measurement: knowledge, attitudes and barriers in patients and practitioners in a multi-ethnic population. Family Practice, 2009, 26, 365-371.	0.8	39
206	Rationale and study design for a randomised controlled trial to reduce sedentary time in adults at risk of type 2 diabetes mellitus: project stand (Sedentary Time ANd diabetes). BMC Public Health, 2011, 11, 908.	1.2	39
207	Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: A retrospective study. Primary Care Diabetes, 2013, 7, 159-165.	0.9	39
208	Selfâ€ŧitration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. Diabetes, Obesity and Metabolism, 2013, 15, 690-700.	2.2	39
209	Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 925-937.	5.5	39
210	Activity Intensity, Volume, and Norms: Utility and Interpretation of Accelerometer Metrics. Medicine and Science in Sports and Exercise, 2019, 51, 2410-2422.	0.2	39
211	Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment. Diabetes Therapy, 2020, 11, 15-35.	1.2	39
212	Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technology Assessment, 2018, 22, 1-160.	1.3	39
213	Variation in the estimated prevalence of multimorbidity: systematic review and meta-analysis of 193 international studies. BMJ Open, 2022, 12, e057017.	0.8	39
214	Stand up for your health: Is it time to rethink the physical activity paradigm?. Diabetes Research and Clinical Practice, 2011, 93, 292-294.	1.1	38
215	Independent Effect of Ethnicity on Glycemia in South Asians and White Europeans. Diabetes Care, 2012, 35, 1746-1748.	4.3	38
216	A systematic review of interventions targeting primary care or community based professionals on cardio-metabolic risk factor control in people with diabetes. Diabetes Research and Clinical Practice, 2016, 113, 1-13.	1.1	38

#	Article	IF	CITATIONS
217	Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. Acta Diabetologica, 2017, 54, 209-214.	1.2	38
218	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating secondâ€line therapy after metformin monotherapy: <scp>R</scp> etrospective data for 10 256 individuals from the <scp>U</scp> nited <scp>K</scp> ingdom and <scp>G</scp> ermany. Diabetes, Obesity and Metabolism, 2018, 20, 389-399.	2.2	38
219	Long COVID $\hat{a} \in$ " metabolic risk factors and novel therapeutic management. Nature Reviews Endocrinology, 2021, 17, 379-380.	4.3	38
220	Global accessibility of therapeutics for diabetes mellitus. Nature Reviews Endocrinology, 2022, 18, 199-204.	4.3	38
221	Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: a cross-sectional analysis of adults at risk of type 2 diabetes. BMJ Open, 2017, 7, e014267.	0.8	37
222	Effects of glucoseâ€lowering and multifactorial interventions on cardiovascular and mortality outcomes: a metaâ€analysis of randomized control trials. Diabetic Medicine, 2016, 33, 280-289.	1.2	36
223	Changes in HbA1c and weight, and treatment persistence, over the 18Âmonths following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Medicine, 2018, 16, 116.	2.3	36
224	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a secondâ€line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2019, 21, 2474-2485.	2.2	36
225	Who should be prioritised for COVID-19 vaccines?. Lancet, The, 2020, 396, 1732-1733.	6.3	36
226	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	3.2	36
227	Quality of care of patients with diabetes: collation of data from multi-practice audits of diabetes in primary care. Family Practice, 1999, 16, 54-59.	0.8	35
228	What have we learnt from "real world―data, observational studies and metaâ€analyses. Diabetes, Obesity and Metabolism, 2018, 20, 47-58.	2.2	35
229	Assessing risk for healthcare workers during the covid-19 pandemic. BMJ, The, 2021, 372, n602.	3.0	35
230	Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample. Endocrine Connections, 2017, 6, 323-330.	0.8	34
231	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVIDâ€19: Analysis of the ISARIC CCPâ€UK Cohort. Obesity, 2021, 29, 1223-1230.	1.5	34
232	A Text-Messaging and Pedometer Program to Promote Physical Activity in People at High Risk of Type 2 Diabetes: The Development of the PROPELS Follow-On Support Program. JMIR MHealth and UHealth, 2015, 3, e105.	1.8	34
233	Educational interventions for migrant South Asians with Type 2 diabetes: a systematic review. Diabetic Medicine, 2008, 25, 985-992.	1.2	33
234	Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovascular Diabetology, 2012, 11, 56.	2.7	33

#	Article	IF	CITATIONS
235	Meta-analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. British Journal of Surgery, 2019, 106, 181-189.	0.1	33
236	Assessing the costâ€effectiveness of sodium–glucose cotransporterâ€2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 2364-2374.	2.2	33
237	Risk of cancer incidence and mortality associated with diabetes: A systematic review with trend analysis of 203 cohorts. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 14-22.	1.1	33
238	Vitamin D and covid-19. BMJ, The, 2021, 372, n544.	3.0	33
239	Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. Clinical Endocrinology, 2015, 83, 542-549.	1.2	32
240	A data-driven, meaningful, easy to interpret, standardised accelerometer outcome variable for global surveillance. Journal of Science and Medicine in Sport, 2019, 22, 1132-1138.	0.6	32
241	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.1	32
242	Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 561-570.	5.5	32
243	Biomedical, lifestyle and psychosocial characteristics of people newly diagnosed with Type 2 diabetes: baseline data from the DESMOND randomized controlled trial. Diabetic Medicine, 2008, 25, 1454-1461.	1.2	31
244	Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Annals of Medicine, 2018, 50, 529-537.	1.5	31
245	Strategies to record and use ethnicity information in routine health data. Nature Medicine, 2022, 28, 1338-1342.	15.2	31
246	TypeÂ2 diabetes mellitus and obesity in young adults: the extreme phenotype with early cardiovascular dysfunction. Diabetic Medicine, 2014, 31, 794-798.	1.2	30
247	Safety and effectiveness of nonâ€insulin glucoseâ€iowering agents in the treatment of people with type 2 diabetes who observe <scp>R</scp> amadan: a systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2015, 17, 639-648.	2.2	30
248	The association between air pollution and type 2 diabetes in a large cross-sectional study in Leicester: The CHAMPIONS Study. Environment International, 2017, 104, 41-47.	4.8	30
249	Cardiovascular efficacy and safety of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: a systematic review and network metaâ€analysis. Diabetic Medicine, 2019, 36, 444-452.	1.2	30
250	Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 17-26.	5.5	30
251	Pandemic threatens primary care for long term conditions. BMJ, The, 2020, 371, m3793.	3.0	30

3.0 30

#	Article	IF	CITATIONS
253	Priorities of patients with multimorbidity and of clinicians regarding treatment and health outcomes: a systematic mixed studies review. BMJ Open, 2020, 10, e033445.	0.8	30
254	Managing People with Diabetes Fasting for Ramadan During the COVIDâ€19 Pandemic: A South Asian Health Foundation Update. Diabetic Medicine, 2020, 37, 1094-1102.	1.2	30
255	The need for improved collection and coding of ethnicity in health research. Journal of Public Health, 2021, 43, e270-e272.	1.0	30
256	Association of Timing and Balance of Physical Activity and Rest/Sleep With Risk of COVID-19: A UK Biobank Study. Mayo Clinic Proceedings, 2021, 96, 156-164.	1.4	30
257	Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. British Journal of General Practice, 2006, 56, 511-7.	0.7	30
258	Short report. Effect of systematic review of medication by general practitioner on drug consumption among nursing-home residents. Age and Ageing, 2000, 29, 451-453.	0.7	29
259	Systematic review of open access echocardiography for primary care. European Journal of Heart Failure, 2004, 6, 79-83.	2.9	29
260	The Prevalence of Depression in White-European and South-Asian People with Impaired Glucose Regulation and Screen-Detected Type 2 Diabetes Mellitus. PLoS ONE, 2009, 4, e7755.	1.1	29
261	Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes. Diabetes Care, 2019, 42, 349-351.	4.3	29
262	Walking pace improves all-cause and cardiovascular mortality risk prediction: A UK Biobank prognostic study. European Journal of Preventive Cardiology, 2020, 27, 1036-1044.	0.8	29
263	A population-based cohort study of obesity, ethnicity and COVID-19 mortality in 12.6 million adults in England. Nature Communications, 2022, 13, 624.	5.8	29
264	Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocrine Disorders, 2022, 22, 111.	0.9	29
265	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people. Primary Care Diabetes, 2019, 13, 330-352.	0.9	28
266	Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica, 2019, 56, 839-850.	1.2	28
267	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a realâ€world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1429-1436.	2.2	28
268	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technology Assessment, 2018, 22, 1-64.	1.3	28
269	Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis. PLoS Medicine, 2022, 19, e1004015.	3.9	28
270	A cluster randomised controlled trial to investigate the effectiveness and cost effectiveness of the â€~Girls Active' intervention: a study protocol. BMC Public Health, 2015, 15, 526.	1.2	27

#	Article	IF	CITATIONS
271	Body mass index and the risk of <scp>COVID</scp> â€19 across ethnic groups: Analysis of <scp>UK</scp> Biobank. Diabetes, Obesity and Metabolism, 2020, 22, 1953-1954.	2.2	27
272	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Primary Care Diabetes, 2021, 15, 31-51.	0.9	27
273	Providing a Basis for Harmonization of Accelerometer-Assessed Physical Activity Outcomes Across Epidemiological Datasets. Journal for the Measurement of Physical Behaviour, 2019, 2, 131-142.	0.5	27
274	Healthcare workers' views on mandatory SARS-CoV-2 vaccination in the UK: A cross-sectional, mixed-methods analysis from the UK-REACH study. EClinicalMedicine, 2022, 46, 101346.	3.2	27
275	Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans. PLoS ONE, 2013, 8, e55580.	1.1	26
276	Representation of people of South Asian origin in cardiovascular outcome trials of glucoseâ€lowering therapies in Type 2 diabetes. Diabetic Medicine, 2017, 34, 64-68.	1.2	26
277	Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. Diabetologia, 2018, 61, 1592-1602.	2.9	26
278	Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes and Endocrinology,the, 2018, 6, 266-268.	5.5	26
279	Serum albumin, cardiometabolic and other adverse outcomes: systematic review and meta-analyses of 48 published observational cohort studies involving 1,492,237 participants. Scandinavian Cardiovascular Journal, 2020, 54, 280-293.	0.4	26
280	Association of Cardiometabolic Multimorbidity and Depression With Cardiovascular Events in Early-Onset Adult Type 2 Diabetes: A Multiethnic Study in the U.S Diabetes Care, 2021, 44, 231-239.	4.3	26
281	The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings. BMJ Open, 2021, 11, e050647.	0.8	26
282	Adherence to type 2 diabetes management. British Journal of Diabetes, 2019, 19, 99-104.	0.1	26
283	COVID-19 vaccination uptake amongst ethnic minority communities in England: a linked study exploring the drivers of differential vaccination rates. Journal of Public Health, 2023, 45, e65-e74.	1.0	26
284	Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes, Obesity and Metabolism, 2010, 12, 474-484.	2.2	25
285	Differences in levels of physical activity between White and South Asian populations within a healthcare setting: impact of measurement type in a cross-sectional study. BMJ Open, 2015, 5, e006181.	0.8	25
286	Mortality risk comparing walking pace to handgrip strength and a healthy lifestyle: A UK Biobank study. European Journal of Preventive Cardiology, 2021, 28, 704-712.	0.8	25
287	Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes. Diabetes Care, 2020, 43, 2248-2256.	4.3	25
288	Association of maternal lipid profile and gestational diabetes mellitus: A systematic review and meta-analysis of 292 studies and 97,880 women. EClinicalMedicine, 2021, 34, 100830.	3.2	25

#	Article	IF	CITATIONS
289	Prevention of Microvascular Complications of Diabetes. Endocrinology and Metabolism Clinics of North America, 2021, 50, 431-455.	1.2	25
290	Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese highâ€risk adults: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1732-1739.	2.2	24
291	Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: a matched case–control analysis. Cardiovascular Diabetology, 2018, 17, 70.	2.7	24
292	Effectiveness of psychoeducational interventions for the treatment of diabetes-specific emotional distress and glycaemic control in people with type 2 diabetes: A systematic review and meta-analysis. Primary Care Diabetes, 2019, 13, 556-567.	0.9	24
293	Differences in objectively measured physical activity and sedentary behaviour between white Europeans and south Asians recruited from primary care: cross-sectional analysis of the PROPELS trial. BMC Public Health, 2019, 19, 95.	1.2	24
294	The importance of the initial period of basal insulin titration in people with diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 722-733.	2.2	24
295	Temporal Trend in Young-Onset Type 2 Diabetes—Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records. Diabetes Care, 2020, 43, 2208-2216.	4.3	24
296	Early lessons from a second COVID-19 lockdown in Leicester, UK. Lancet, The, 2020, 396, e4-e5.	6.3	24
297	SGLT2 inhibitors in people with and without T2DM. Nature Reviews Endocrinology, 2021, 17, 75-76.	4.3	24
298	Using Intervention Mapping to Develop a Digital Self-Management Program for People With Type 2 Diabetes: Tutorial on MyDESMOND. Journal of Medical Internet Research, 2020, 22, e17316.	2.1	24
299	The impact of the COVIDâ€19 pandemic on glycaemic control in people with diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1850-1860.	2.2	24
300	Development of a lifestyle intervention using the MRC framework for diabetes prevention in people with impaired glucose regulation. Journal of Public Health, 2016, 38, 493-501.	1.0	23
301	Incident Type 2 diabetes and the effect of early regression to normoglycaemia in a population with impaired glucose regulation. Diabetic Medicine, 2017, 34, 396-404.	1.2	23
302	Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension, 2018, 72, 1117-1124.	1.3	23
303	Online patient education interventions in type 2 diabetes or cardiovascular disease: A systematic review of systematic reviews. Primary Care Diabetes, 2019, 13, 16-27.	0.9	23
304	The right place for Sulphonylureas today: Part of â€~Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus'. Diabetes Research and Clinical Practice, 2019, 157, 107836.	1.1	23
305	Leisureâ€time physical activity and life expectancy in people with cardiometabolic multimorbidity and depression. Journal of Internal Medicine, 2020, 287, 87-99.	2.7	23
306	Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. Diabetes Care, 2020, 43, 418-425.	4.3	23

#	Article	IF	CITATIONS
307	Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1255-1268.	1.8	23
308	Comparison of glucoseâ€lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 985-997.	2.2	23
309	Unanswered questions over NHS health checks. BMJ: British Medical Journal, 2010, 342, c6312-c6312.	2.4	23
310	Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations. British Journal of General Practice, 2000, 50, 50-4.	0.7	23
311	Evolving mortality and clinical outcomes of hospitalized subjects during successive COVID-19 waves in Catalonia, Spain. Global Epidemiology, 2022, 4, 100071.	0.6	23
312	Screening for the metabolic syndrome using simple anthropometric measurements in south Asian and white Europeans: A population-based screening study. The Leicester Ethnic Atherosclerosis and Diabetes Risk (LEADER) Study. Primary Care Diabetes, 2010, 4, 25-32.	0.9	22
313	PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. Trials, 2015, 16, 289.	0.7	22
314	Management of type 2 diabetes: <scp>t</scp> he current situation and key opportunities to improve care in the <scp>UK</scp> . Diabetes, Obesity and Metabolism, 2016, 18, 1157-1166.	2.2	22
315	Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trial. BMJ Open, 2017, 7, e013592.	0.8	22
316	Compliance of Adolescent Girls to Repeated Deployments of Wrist-Worn Accelerometers. Medicine and Science in Sports and Exercise, 2018, 50, 1508-1517.	0.2	22
317	Impact of Depression and Anxiety on Change to Physical Activity Following a Pragmatic Diabetes Prevention Program Within Primary Care: Pooled Analysis From Two Randomized Controlled Trials. Diabetes Care, 2019, 42, 1847-1853.	4.3	22
318	Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study. BMJ Open, 2019, 9, e027773.	0.8	22
319	First-line treatment for type 2 diabetes: is it too early to abandon metformin?. Lancet, The, 2020, 396, 1705-1707.	6.3	22
320	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3025-3035.	1.8	22
321	Incidence of stroke among Saudi population: a systematic review and meta-analysis. Neurological Sciences, 2020, 41, 3099-3104.	0.9	22
322	The impact of COVIDâ€19 restrictions on accelerometerâ€assessed physical activity and sleep in individuals with type 2 diabetes. Diabetic Medicine, 2021, 38, e14549.	1.2	22
323	Should vaccination for healthcare workers be mandatory?. Journal of the Royal Society of Medicine, 2021, 114, 235-236.	1.1	22
324	Lower risk of hospitalization for heart failure, kidney disease and death with sodiumâ€glucose coâ€ŧransporterâ€2 inhibitors compared with dipeptidyl peptidaseâ€4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care. Diabetes, Obesity and Metabolism, 2021, 23, 2207-2214.	2.2	22

#	Article	IF	CITATIONS
325	Validity of selfâ€assessed waist circumference in a multiâ€ethnic UK population. Diabetic Medicine, 2012, 29, 404-409.	1.2	21
326	Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. PLoS ONE, 2015, 10, e0135702.	1.1	21
327	Integrated primary care: is this the solution to the diabetes epidemic?. Diabetic Medicine, 2017, 34, 748-750.	1.2	21
328	Self-knowledge of HbA1c in people with Type 2 Diabetes Mellitus and its association with glycaemic control. Primary Care Diabetes, 2017, 11, 414-420.	0.9	21
329	Cohort profile: National Diabetes Audit for England and Wales. Diabetic Medicine, 2021, 38, e14616.	1.2	21
330	Evaluation of the Clinical and Cost Effectiveness of Intermediate Care Clinics for Diabetes (ICCD): A Multicentre Cluster Randomised Controlled Trial. PLoS ONE, 2014, 9, e93964.	1.1	21
331	Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit. Diabetes Care, 2022, 45, 1151-1161.	4.3	21
332	Primary prevention of type-2 diabetes and heart disease: action research in secondary schools serving an ethnically diverse UK population. Journal of Public Health, 2008, 30, 30-37.	1.0	20
333	Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation. Journal of Sports Sciences, 2018, 36, 1586-1593.	1.0	20
334	Glycaemic control in patients with type 2 diabetes initiating secondâ€line therapy: Results from the global DISCOVER study programme. Diabetes, Obesity and Metabolism, 2020, 22, 66-78.	2.2	20
335	Evaluation of an 8-Week Vegan Diet on Plasma Trimethylamine-N-Oxide and Postchallenge Glucose in Adults with Dysglycemia or Obesity. Journal of Nutrition, 2021, 151, 1844-1853.	1.3	20
336	Ethnic minorities and COVID-19: examining whether excess risk is mediated through deprivation. European Journal of Public Health, 2021, 31, 630-634.	0.1	20
337	Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Research and Clinical Practice, 2018, 138, 35-43.	1.1	19
338	Process evaluation of the school-based Girls Active programme. BMC Public Health, 2019, 19, 1187.	1.2	19
339	Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12â€month prospective observational study. Diabetes, Obesity and Metabolism, 2019, 21, 1585-1595.	2.2	19
340	Educational weight loss interventions in obese and overweight adults with type 2 diabetes: a systematic review and metaâ€analysis of randomized controlled trials. Diabetic Medicine, 2020, 37, 623-635.	1.2	19
341	Empagliflozin treatment effects across categories of baseline <scp>HbA1c</scp> , body weight and blood pressure as an addâ€on to metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 425-433.	2.2	19
342	Association of working shifts, inside and outside of healthcare, with severe COVIDâ~'19: an observational study. BMC Public Health, 2021, 21, 773.	1.2	19

#	Article	IF	CITATIONS
343	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. BMC Infectious Diseases, 2021, 21, 717.	1.3	19
344	Feature selection for unsupervised machine learning of accelerometer data physical activity clusters – A systematic review. Gait and Posture, 2021, 90, 120-128.	0.6	19
345	Understanding and tracking the impact of long COVID in the United Kingdom. Nature Medicine, 2022, 28, 11-15.	15.2	19
346	Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. Diabetologia, 2013, 56, 2367-2377.	2.9	18
347	Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis. Acta Diabetologica, 2019, 56, 331-339.	1.2	18
348	Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic. Diabetes Care, 2021, 44, e133-e135.	4.3	18
349	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007.	1.0	18
350	A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia, 2021, 64, 1717-1724.	2.9	18
351	Association Between Accelerometer-Assessed Physical Activity and Severity of COVID-19 in UK Biobank. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 997-1007.	1.2	18
352	Should we screen for type 2 diabetes: Yes. BMJ, The, 2012, 345, e4514-e4514.	3.0	17
353	COVID-19 cumulative mortality rates for frontline healthcare staff in England. British Journal of General Practice, 2020, 70, 327.2-328.	0.7	17
354	FilterK: A new outlier detection method for k-means clustering of physical activity. Journal of Biomedical Informatics, 2020, 104, 103397.	2.5	17
355	Use of MyDesmond digital education programme to support selfâ€management in people with type 2 diabetes during the COVIDâ€19 pandemic. Diabetic Medicine, 2021, 38, e14469.	1.2	17
356	Deviceâ€measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabetic Medicine, 2021, 38, e14393.	1.2	17
357	Device-assessed total and prolonged sitting time: associations with anxiety, depression, and health-related quality of life in adults. Journal of Affective Disorders, 2021, 287, 107-114.	2.0	17
358	Clustering of comorbidities. Future Healthcare Journal, 2021, 8, e224-e229.	0.6	17
359	Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme. Lancet Diabetes and Endocrinology,the, 2021, 9, 649-651.	5.5	17
360	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy, 2020, 11, 33-48.	1.2	17

#	Article	IF	CITATIONS
361	Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in TypeÂ2 Diabetes. Diabetes Therapy, 2022, 13, 619-634.	1.2	17
362	A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney International, 2022, 102, 652-660.	2.6	17
363	Diabetes self-management education: acceptability of using trained lay educators. Postgraduate Medical Journal, 2014, 90, 638-642.	0.9	16
364	Associations Between Anthropometric Measurements and Cardiometabolic Risk Factors in White European and South Asian Adults in the United Kingdom. Mayo Clinic Proceedings, 2017, 92, 925-933.	1.4	16
365	Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes. Diabetes Care, 2019, 42, 1132-1135.	4.3	16
366	Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 569-575.	2.6	16
367	Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes. Primary Care Diabetes, 2020, 14, 370-375.	0.9	16
368	The present and future scope of realâ€world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?. Diabetes, Obesity and Metabolism, 2020, 22, 21-34.	2.2	16
369	Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Diabetes Care, 2021, 44, 915-924.	4.3	16
370	Completion of annual diabetes care processes and mortality: A cohort study using the <scp>National Diabetes Audit for England and Wales</scp> . Diabetes, Obesity and Metabolism, 2021, 23, 2728-2740.	2.2	16
371	The importance of physical activity in management of type 2 diabetes and COVID-19. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110546.	1.4	16
372	COVID-19 vaccine uptake and hesitancy opinions from frontline health care and social care workers: Survey data from 37 countries. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102361.	1.8	16
373	The impact of the COVID pandemic on primary care diabetes services in the UK: A cross-sectional national survey of views of health professionals delivering diabetes care. Primary Care Diabetes, 2022, 16, 257-263.	0.9	16
374	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 2022, 24, 2071-2080.	2.2	16
375	Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority. BMJ: British Medical Journal, 1999, 319, 297-297.	2.4	15
376	Coronary heart disease in people of south-Asian origin. Lancet, The, 2004, 364, 2077-2078.	6.3	15
377	The diabetes mellitus tsunami: worse than the 'Spanish flu' pandemic?. Nature Reviews Endocrinology, 2016, 12, 377-378.	4.3	15
378	Evaluating the impact of an enhanced primary care diabetes service on diabetes outcomes: A before–after study. Primary Care Diabetes, 2017, 11, 171-177.	0.9	15

#	Article	IF	CITATIONS
379	Type 2 diabetes and glucose intolerance in a population with intellectual disabilities: the STOP diabetes crossâ€sectional screening study. Journal of Intellectual Disability Research, 2017, 61, 668-681.	1.2	15
380	Structured education programme for women with polycystic ovary syndrome: a randomised controlled trial. Endocrine Connections, 2018, 7, 26-35.	0.8	15
381	Prevalence and progression of diabetic nephropathy in South Asian, white European and African Caribbean people with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 658-673.	2.2	15
382	Efficacy of low―and veryâ€Iowâ€energy diets in people with type 2 diabetes mellitus: A systematic review and metaâ€analysis of interventional studies. Diabetes, Obesity and Metabolism, 2019, 21, 1695-1705.	2.2	15
383	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. Diabetes Therapy, 2019, 10, 1-13.	1.2	15
384	Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large realâ€world studies. Diabetes, Obesity and Metabolism, 2019, 21, 844-853.	2.2	15
385	Distal technology interventions in people with diabetes: an umbrella review of multiple health outcomes. Diabetic Medicine, 2020, 37, 1966-1976.	1.2	15
386	Multimorbidity and SARS-CoV-2 infection in UK Biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 775-776.	1.8	15
387	Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia, 2020, 63, 2129-2139.	2.9	15
388	Adults with early-onset type 2 diabetes (aged 18–39Âyears) are severely underrepresented in diabetes clinical research trials. Diabetologia, 2020, 63, 1516-1520.	2.9	15
389	Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular Diabetology, 2021, 20, 159.	2.7	15
390	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244.	0.9	15
391	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovascular Diabetology, 2016, 15, 102.	2.7	14
392	Risk factors and outcome differences in hypoglycaemiaâ€related hospital admissions: <scp>A</scp> caseâ€control study in <scp>E</scp> ngland. Diabetes, Obesity and Metabolism, 2017, 19, 1371-1378.	2.2	14
393	Therapeutic inertia amongst general practitioners with interest in diabetes. Primary Care Diabetes, 2018, 12, 87-91.	0.9	14
394	Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. BMJ Open Diabetes Research and Care, 2019, 7, e000627.	1.2	14
395	Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?. Pharmaceuticals, 2020, 13, 427.	1.7	14
396	Promoting physical activity in a multi-ethnic population at high risk of diabetes: the 48-month PROPELS randomised controlled trial. BMC Medicine, 2021, 19, 130.	2.3	14

#	Article	IF	CITATIONS
397	A school-based intervention (â€~Girls Active') to increase physical activity levels among 11- to 14-year-old girls: cluster RCT. Public Health Research, 2019, 7, 1-162.	0.5	14
398	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. American Heart Journal, 2022, 243, 232-239.	1.2	14
399	Association between household size and COVID-19: A UK Biobank observational study. Journal of the Royal Society of Medicine, 2022, 115, 138-144.	1.1	14
400	Effect of insulin glargine on glycaemic control and weight in obese and nonâ€obese people with type 2 diabetes: data from the AT.LANTUS trial. Diabetes, Obesity and Metabolism, 2010, 12, 683-688.	2.2	13
401	Association of cardiac and non-cardiac chronic disease comorbidity on glycaemic control in a multi-ethnic population with type 1 and type 2 diabetes. Postgraduate Medical Journal, 2011, 87, 763-768.	0.9	13
402	Realâ€world evaluation of the DESMOND type 2 diabetes education and selfâ€management programme. Practical Diabetes, 2018, 35, 19.	0.1	13
403	Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the) Tj ETQq1 1 0.784	43 b48 gBT	/O væ rlock 10
404	Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs, 2019, 79, 173-186.	4.9	13
405	Predictors of the Acute Postprandial Response to Breaking Up Prolonged Sitting. Medicine and Science in Sports and Exercise, 2020, 52, 1385-1393.	0.2	13
406	Comparative effectiveness of gliclazide modified release versus sitagliptin as secondâ€line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2417-2426.	2.2	13
407	Prospectively Reallocating Sedentary Time: Associations with Cardiometabolic Health. Medicine and Science in Sports and Exercise, 2020, 52, 844-850.	0.2	13
408	A randomized, openâ€label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	2.2	13
409	The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan. Diabetes Research and Clinical Practice, 2020, 164, 108145.	1.1	13
410	Self-Compassion, Metabolic Control and Health Status in Individuals with Type 2 Diabetes: A UK Observational Study. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 413-419.	0.6	13
411	Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation. Diabetic Medicine, 2021, 38, e14497.	1.2	13
412	Experiences of using a digital type 2 diabetes prevention application designed to support women with previous gestational diabetes. BMC Health Services Research, 2021, 21, 772.	0.9	13
413	Change in Sedentary Time, Physical Activity, Bodyweight, and HbA1c in High-Risk Adults. Medicine and Science in Sports and Exercise, 2017, 49, 1120-1125.	0.2	13
414	Equivalency of Sleep Estimates: Comparison of Three Research-Grade Accelerometers. Journal for the Measurement of Physical Behaviour, 2020, 3, 294-303.	0.5	13

#	Article	IF	CITATIONS
415	The impact of COVID-19 on primary care: Insights from the National Health Service (NHS) and future recommendations. Journal of Family Medicine and Primary Care, 2021, 10, 4345.	0.3	13
416	Comparative effectiveness of cardiovascular, renal and safety outcomes of secondâ€line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network metaâ€analysis of randomised controlled trials. Diabetic Medicine, 2022, 39, e14780.	1.2	13
417	Effects of Supervised Exercise on the Development of Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 793.	1.0	13
418	Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Primary Care Diabetes, 2014, 8, 57-63.	0.9	12
419	Physical Activity after Cardiac EventS (PACES) – a group education programme with subsequent text-message support designed to increase physical activity in individuals with diagnosed coronary heart disease: study protocol for a randomised controlled trial. Trials, 2018, 19, 537.	0.7	12
420	Association of circulating osteocalcin with cardiovascular disease and intermediate cardiovascular phenotypes: systematic review and meta-analysis. Scandinavian Cardiovascular Journal, 2019, 53, 286-295.	0.4	12
421	Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme. Diabetes, Obesity and Metabolism, 2019, 21, 2349-2353.	2.2	12
422	<p>Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening</p> . Patient Preference and Adherence, 2019, Volume 13, 537-547.	0.8	12
423	The multimorbidity epidemic: challenges for real-world research. Primary Health Care Research and Development, 2020, 21, e6.	0.5	12
424	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. Diabetes Care, 2021, 44, e32-e34.	4.3	12
425	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Health Technology Assessment, 2016, 20, 1-86.	1.3	12
426	Benefits and harms of sodiumâ€glucose coâ€transporterâ€2 inhibitors (SGLT2â€I) and renin–angiotensin–aldosterone system inhibitors (RAASâ€I) versus SGLT2â€Is alone in patients with type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Endocrinology, Diabetes and Metabolism, 2022, 5, e00303.	1.0	12
427	Open science communication: The first year of the UK's Independent Scientific Advisory Group for Emergencies. Health Policy, 2022, 126, 234-244.	1.4	12
428	Attitudes of older adults and their carers towards deâ€prescribing: A systematic review. Diabetic Medicine, 2022, 39, e14801.	1.2	12
429	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. Diabetes, Obesity and Metabolism, 2022, 24, 1187-1196.	2.2	12
430	A community faith centre based screening and educational intervention to reduce the risk of type 2 diabetes: A feasibility study. Diabetes Research and Clinical Practice, 2016, 120, 73-80.	1.1	11
431	Associations of objectively measured moderate-to-vigorous-intensity physical activity and sedentary time with all-cause mortality in a population of adults at high risk of type 2 diabetes mellitus. Preventive Medicine Reports, 2017, 5, 285-288.	0.8	11
432	Baby Steps – a structured group education programme with accompanying mobile web application designed to promote physical activity in women with a history of gestational diabetes: study protocol for a randomised controlled trial. Trials, 2018, 19, 682.	0.7	11

#	Article	IF	CITATIONS
433	Relevance of physical function in the association of red and processed meat intake with all–cause, cardiovascular, and cancer mortality. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1308-1315.	1.1	11
434	Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more nonâ€insulin antidiabetic drugs in a realâ€world setting. Diabetes, Obesity and Metabolism, 2019, 21, 1373-1380.	2.2	11
435	Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. Canadian Journal of Diabetes, 2019, 43, 384-391.	0.4	11
436	Prediction of Diabetic Foot Ulceration: The Value of Using Microclimate Sensor Arrays. Journal of Diabetes Science and Technology, 2020, 14, 55-64.	1.3	11
437	Influence of sociodemographic characteristics on the preferred format of health education delivery in individuals with type 2 diabetes mellitus and or cardiovascular disease: a questionnaire study. Diabetic Medicine, 2020, 37, 982-990.	1.2	11
438	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 39-48.	2.2	11
439	Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT). Diabetes Care, 2021, 44, 1419-1425.	4.3	11
440	Screening for glucose intolerance and development of a lifestyle education programme for prevention of type 2 diabetes in a population with intellectual disabilities: the STOP Diabetes research project. Programme Grants for Applied Research, 2017, 5, 1-316.	0.4	11
441	Indirect effects of the COVID-19 pandemic on people with type 2 diabetes: time to urgently move into a recovery phase. BMJ Quality and Safety, 2022, 31, 483-485.	1.8	11
442	Effect of the PPARG2 Pro12Ala Polymorphism on Associations of Physical Activity and Sedentary Time with Markers of Insulin Sensitivity in Those with an Elevated Risk of Type 2 Diabetes. PLoS ONE, 2015, 10, e0124062.	1.1	10
443	Explaining engagement in self-monitoring among participants of the DESMOND Self-monitoring Trial: a qualitative interview study. Family Practice, 2015, 32, 596-602.	0.8	10
444	Optimizing management of glycaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 397-411.	2.2	10
445	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. Primary Care Diabetes, 2018, 12, 383-392.	0.9	10
446	Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A realâ€world study of patients followed for up to 19 years. Diabetes, Obesity and Metabolism, 2021, 23, 218-227.	2.2	10
447	Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the <scp>LYDIA</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1409-1414.	2.2	10
448	Temporal trends in coâ€norbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis in the <scp>UK</scp> . Diabetes, Obesity and Metabolism, 2021, 23, 1150-1161.	2.2	10
449	Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Realâ€world evidence from primary care. Diabetes, Obesity and Metabolism, 2021, 23, 1518-1531.	2.2	10
450	Microvascular Disease and Risk of Cardiovascular Events and Death From Intensive Treatment in Type 2 Diabetes. Mayo Clinic Proceedings, 2021, 96, 1458-1469.	1.4	10

#	Article	IF	CITATIONS
451	Individual, healthcare professional and systemâ€level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and metaâ€ethnography. Diabetic Medicine, 2022, 39, e14678.	1.2	10
452	Framework to aid analysis and interpretation of ongoing COVID-19 research. Wellcome Open Research, 0, 5, 208.	0.9	10
453	Covid-19 and ethnicity: we must seek to understand the drivers of higher transmission. BMJ, The, 2021, 375, n2709.	3.0	10
454	Collation and comparison of multi-practice audit data: prevalence and treatment of known diabetes mellitus. British Journal of General Practice, 1999, 49, 375-9.	0.7	10
455	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart, 2022, 108, 1200-1208.	1.2	10
456	New Digital Health Technologies for Insulin Initiation and Optimization for People With Type 2 Diabetes. Endocrine Practice, 2022, 28, 811-821.	1.1	10
457	Reducing sedentary time in adults at risk of type 2 diabetes: process evaluation of the STAND (Sedentary Time ANd Diabetes) RCT. BMC Public Health, 2017, 17, 80.	1.2	9
458	Associations of moderate-to-vigorous-intensity physical activity and body mass index with glycated haemoglobin within the general population: a cross-sectional analysis of the 2008 Health Survey for England. BMJ Open, 2017, 7, e014456.	0.8	9
459	Comorbidities, complications and mortality in people of South Asian ethnicity with type 1 diabetes compared with other ethnic groups: a systematic review. BMJ Open, 2017, 7, e015005.	0.8	9
460	Weight loss and mortality risk in patients with different adiposity at diagnosis of type 2 diabetes: a longitudinal cohort study. Nutrition and Diabetes, 2018, 8, 37.	1.5	9
461	<p>De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study</p> . Patient Preference and Adherence, 2019, Volume 13, 1775-1783.	0.8	9
462	Temporal variation of renal function in people with type 2 diabetes mellitus: A retrospective UK clinical practice research datalink cohort study. Diabetes, Obesity and Metabolism, 2019, 21, 1817-1823.	2.2	9
463	Number needed to treat in cardiovascular outcome trials of glucagonâ€like peptideâ€1 receptor agonists: A systematic review with temporal analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1670-1677.	2.2	9
464	Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (<scp>SARSâ€CoV</scp> â€2 or <scp>COVID</scp> â€19). Diabetes, Obesity and Metabolism, 2020, 22, 1942-1945.	2.2	9
465	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. Primary Care Diabetes, 2021, 15, 59-68.	0.9	9
466	In-shoe pressure thresholds for people with diabetes and neuropathy at risk of ulceration: A systematic review. Journal of Diabetes and Its Complications, 2021, 35, 107815.	1.2	9
467	United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): a retrospective cohort study using linked routinely collected data, study protocol. BMJ Open, 2021, 11, e046392.	0.8	9
468	Comparison of mortality in people with type 1 and type 2 diabetes by age of diagnosis: an incident population-based study in England and Wales. Lancet Diabetes and Endocrinology,the, 2022, 10, 95-97.	5.5	9

#	Article	IF	CITATIONS
469	Impact of micro―and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study. Endocrinology, Diabetes and Metabolism, 2022, 5, e00321.	1.0	9
470	Non-pharmacological therapies for postviral syndromes, including Long COVID: a systematic review and meta-analysis protocol. BMJ Open, 2022, 12, e057885.	0.8	9
471	The dipeptidylâ€peptidaseâ€4 (DPPâ€4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 474-482.	0.2	8
472	Assessment of response rates and yields for Two opportunistic Tools for Early detection of Non-diabetic hyperglycaemia and Diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Diabetes Research and Clinical Practice, 2016, 118, 12-20.	1.1	8
473	External national validation of the Leicester Selfâ€Assessment score for Type 2 diabetes using data from the English Longitudinal Study of Ageing. Diabetic Medicine, 2017, 34, 1575-1583.	1.2	8
474	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10. Diabetes Care, 2018, 41, e106-e108.	4.3	8
475	CP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice. BMJ Open, 2018, 8, e021435.	0.8	8
476	Regional variations in definitions and rates of hypoglycaemia: findings from the global <scp>HAT</scp> observational study of 27 585 people with Type 1 and insulinâ€ŧreated Type 2 diabetes mellitus. Diabetic Medicine, 2018, 35, 1232-1241.	1.2	8
477	Towards a Portable Model to Discriminate Activity Clusters from Accelerometer Data. Sensors, 2019, 19, 4504.	2.1	8
478	Effect of pragmatic versus explanatory interventions on medication adherence in people with cardiometabolic conditions: a systematic review and meta-analysis. BMJ Open, 2020, 10, e036575.	0.8	8
479	Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study. Journal of Clinical and Translational Endocrinology, 2020, 20, 100225.	1.0	8
480	Dose distribution and upâ€ŧitration patterns of metformin monotherapy in patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00107.	1.0	8
481	Comparing 24 h physical activity profiles: Office workers, women with a history of gestational diabetes and people with chronic disease condition(s). Journal of Sports Sciences, 2021, 39, 219-226.	1.0	8
482	Prevalence and progression of chronic kidney disease among patients with type <scp>2</scp> diabetes: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1956-1960.	2.2	8
483	Modelling the Reallocation of Time Spent Sitting into Physical Activity: Isotemporal Substitution vs. Compositional Isotemporal Substitution. International Journal of Environmental Research and Public Health, 2021, 18, 6210.	1.2	8
484	Moderate increases in daily step count are associated with reduced IL6 and CRP in women with PCOS. Endocrine Connections, 2018, 7, 1442-1447.	0.8	8
485	Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes. Diabetes Care, 2022, 45, 766-768.	4.3	8
486	New drug treatments versus structured education programmes for type 2 diabetes: comparing cost-effectiveness. Lancet Diabetes and Endocrinology,the, 2016, 4, 557-559.	5.5	7

#	Article	IF	CITATIONS
487	Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification. Diabetes Research and Clinical Practice, 2017, 123, 209-217.	1.1	7
488	A fitting problem: Standardising shoe fit standards to reduce related diabetic foot ulcers. Diabetes Research and Clinical Practice, 2019, 154, 66-74.	1.1	7
489	Postpartum monitoring of women with a history of gestational diabetes — A cross-sectional study of an inner-city population. Primary Care Diabetes, 2019, 13, 376-379.	0.9	7
490	Implementation of research evidence in orthopaedics: a tale of three trials. BMJ Quality and Safety, 2020, 29, 374-381.	1.8	7
491	Disparity in implantable cardioverter defibrillator therapy among minority South Asians in the United Kingdom. Heart, 2020, 106, 671-676.	1.2	7
492	Physical activity and lipidomics in a population at high risk of type 2 diabetes mellitus. Journal of Sports Sciences, 2020, 38, 1150-1160.	1.0	7
493	Associations between secondâ€line glucoseâ€lowering combination therapies with metformin and <scp>HbA1c</scp> , body weight, quality of life, hypoglycaemic events and glucoseâ€lowering treatment intensification: The <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1823-1833.	2.2	7
494	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. Frontiers in Endocrinology, 2021, 12, 708372.	1.5	7
495	Ethnic, social and multimorbidity disparities in therapeutic inertia: A <scp>UK</scp> primary care observational study in patients newly diagnosed with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2437-2445.	2.2	7
496	Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT. Health Technology Assessment, 2021, 25, 1-190.	1.3	7
497	Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study. Frontiers in Endocrinology, 2022, 13, 831676.	1.5	7
498	Estimates of years of life lost depended on the method used: tutorial and comparative investigation. Journal of Clinical Epidemiology, 2022, 150, 42-50.	2.4	7
499	Referral for autopsies: analysis of 651 consecutive deaths in one general practice. Postgraduate Medical Journal, 2000, 76, 415-416.	0.9	6
500	â€~A Safer Ramadan': developing an integrated approach to support safer fasting and feasting for people with type 2 diabetes. Practical Diabetes, 2014, 31, 292-297.	0.1	6
501	A retrospective evaluation of the NHS Health Check Programme in a multi-ethnic population. Journal of Public Health, 2016, 38, 534-542.	1.0	6
502	Type 2 diabetes – Authors' reply. Lancet, The, 2018, 391, 1262.	6.3	6
503	Movement through Active Personalised engagement (MAP) — a self-management programme designed to promote physical activity in people with multimorbidity: study protocol for a randomised controlled trial. Trials, 2018, 19, 576.	0.7	6
504	Glucose dysregulation phenotypes — time to improve outcomes. Nature Reviews Endocrinology, 2018, 14, 632-633.	4.3	6

#	Article	IF	CITATIONS
505	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes, Obesity and Metabolism, 2020, 22, 346-354.	2.2	6
506	Effectiveness of the Ready to Reduce Risk (3R) complex intervention for the primary prevention of cardiovascular disease: a pragmatic randomised controlled trial. BMC Medicine, 2020, 18, 198.	2.3	6
507	Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and allâ€cause mortality: An observational analysis of the ADDITIONâ€Europe trial. Diabetes, Obesity and Metabolism, 2021, 23, 730-741.	2.2	6
508	Improvements in Glycemic Control After Acute Moderate-Intensity Continuous or High-Intensity Interval Exercise Are Greater in South Asians Than White Europeans With Nondiabetic Hyperglycemia: A Randomized Crossover Study. Diabetes Care, 2021, 44, 201-209.	4.3	6
509	The impact of Covid-19 and lockdown measures on self-reported life satisfaction and social relationships does not differ by ethnicity. Journal of Public Health, 2021, 43, e241-e243.	1.0	6
510	Gait Speed as a Predictor for Diabetes Incidence in People with or at Risk of Knee Osteoarthritis: A Longitudinal Analysis from the Osteoarthritis Initiative. International Journal of Environmental Research and Public Health, 2021, 18, 4414.	1.2	6
511	What are the factors associated with longâ€ŧerm glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of secondâ€ŀine therapy? Results from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 2336-2343.	2.2	6
512	Steps per Day Measured by Consumer Activity Trackers Worn at the Non-Dominant and Dominant Wrist Relative to a Waist-Worn Pedometer. Journal for the Measurement of Physical Behaviour, 2018, 1, 2-8.	0.5	6
513	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102484.	1.8	6
514	Risk of hypoglycaemia in people aged ≥65Âyears receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. International Journal of Clinical Practice, 2018, 72, e13240.	0.8	5
515	The Microalbuminuria Education Medication and Optimisation (MEMO) study: 4 years followâ€up of multifactorial intervention in highâ€risk individuals with type 2 diabetes. Diabetic Medicine, 2020, 37, 286-297.	1.2	5
516	Maturational timing, physical self-perceptions and physical activity in UK adolescent females: investigation of a mediated effects model. Annals of Human Biology, 2020, 47, 384-390.	0.4	5
517	COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 2241-2243.	1.8	5
518	Scalable solution for delivery of diabetes self-management education in Thailand (DSME-T): a cluster randomised trial study protocol. BMJ Open, 2020, 10, e036963.	0.8	5
519	Cardiovascular outcome trials of glucose-lowering therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 237-249.	0.7	5
520	Diabetes in adults with intellectual disability: prevalence and associated demographic, lifestyle, independence and health factors. Journal of Intellectual Disability Research, 2020, 64, 287-295.	1.2	5
521	Association and relative importance of multiple risk factor control on cardiovascular disease, end-stage renal disease and mortality in people with type 2 diabetes: A population-based retrospective cohort study. Primary Care Diabetes, 2021, 15, 218-226.	0.9	5
522	Rates and estimated cost of primary care consultations in people diagnosed with type 2 diabetes and comorbidities: A retrospective analysis of 8.9 million consultations. Diabetes, Obesity and Metabolism, 2021, 23, 1301-1310.	2.2	5

#	Article	IF	CITATIONS
523	Glycemic Control and Prevention of Diabetic Complications in Low- and Middle-Income Countries: An Expert Opinion. Diabetes Therapy, 2021, 12, 1491-1501.	1.2	5
524	"lt's so tough for us now―– COVID-19 has negatively impacted religious practices relating to death among minority ethnic groups. Public Health, 2021, 194, 146-148.	1.4	5
525	The effects of a leafletâ€based intervention, â€~Hypos can strike twice', on recurrent hypoglycaemic attendances by ambulance services: A nonâ€randomised stepped wedge study. Diabetic Medicine, 2021, 38, e14612.	1.2	5
526	Perceptions of healthcare professionals and people with type 2 diabetes on emotional support: a qualitative study. BJGP Open, 2020, 4, bjgpopen20X101018.	0.9	5
527	Differences in Accelerometer-Measured Patterns of Physical Activity and Sleep/Rest Between Ethnic Groups and Age: An Analysis of UK Biobank. Journal of Physical Activity and Health, 2022, 19, 37-46.	1.0	5
528	The effectiveness of a structured group education programme for people with established type 2 diabetes in a multi-ethnic population in primary care: A cluster randomised trial. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1549-1559.	1.1	5
529	The effects of empagliflozin, dietary energy restriction, or both on appetiteâ€regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The <scp>SEESAW</scp> randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1509-1521.	2.2	5
530	Association between undiagnosed hypertension and microalbuminuria in South Asians without known diabetes. Journal of Human Hypertension, 2015, 29, 185-189.	1.0	4
531	Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. Diabetologia, 2017, 60, 1007-1015.	2.9	4
532	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). Therapeutics and Clinical Risk Management, 2017, Volume 13, 1569-1576.	0.9	4
533	Reaction time, cardiorespiratory fitness and mortality in UK Biobank: An observational study. Intelligence, 2018, 66, 79-83.	1.6	4
534	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. American Journal of Cardiovascular Drugs, 2018, 18, 13-24.	1.0	4
535	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. BMJ Open, 2018, 8, e023206.	0.8	4
536	Association of depression and anxiety with clinical, sociodemographic, lifestyle and environmental factors in South Asian and white European individuals at high risk of diabetes. Diabetic Medicine, 2019, 36, 1158-1167.	1.2	4
537	Should sodiumâ€glucose coâ€transporterâ€2 inhibitors be considered as firstâ€line oral therapy for people with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2019, 21, 207-209.	2.2	4
538	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. Lancet Diabetes and Endocrinology,the, 2020, 8, 810-811.	5.5	4
539	Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2020, 165, 108250.	1.1	4
540	Impact on guidelines: The general practitioner point of view. Diabetes Research and Clinical Practice, 2020, 166, 108091.	1.1	4

#	Article	IF	CITATIONS
541	Incidence of Depression and Firstâ€Line Antidepressant Therapy in People with Obesity and Depression in Primary Care. Obesity, 2020, 28, 977-984.	1.5	4
542	Physical Activity after Cardiac EventS (PACES): a group education programme with subsequent text message support designed to increase physical activity in individuals with diagnosed coronary heart disease: a randomised controlled trial. Open Heart, 2021, 8, e001351.	0.9	4
543	Improved diabetesâ€related distress and selfâ€efficacy outcomes in a selfâ€management digital programme for people with type 2 diabetes, myDESMOND. Diabetic Medicine, 2021, 38, e14551.	1.2	4
544	Cardiovascular effects of sodiumâ€glucose coâ€transporterâ€2 inhibitors and glucagonâ€like peptideâ€1 receptor agonists: The <i>P</i> value and beyond. Diabetes, Obesity and Metabolism, 2021, 23, 1685-1691.	2.2	4
545	Promoting physical activity with self-management support for those with multimorbidity: a randomised controlled trial. British Journal of General Practice, 2021, 71, e921-e930.	0.7	4
546	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A populationâ€based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	1.2	4
547	Screening male prisoners for depression and anxiety with the PHQ-9 and GAD-7 at NHS Healthcheck: patterns of symptoms and caseness threshold. BMC Psychiatry, 2021, 21, 446.	1.1	4
548	Normative wrist-worn accelerometer values for self-paced walking and running: a walk in the park. Journal of Sports Sciences, 2021, , 1-8.	1.0	4
549	The Ready to Reduce Risk (3R) Study for a Group Educational Intervention With Telephone and Text Messaging Support to Improve Medication Adherence for the Primary Prevention of Cardiovascular Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11289.	0.5	4
550	Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine <scp>U300</scp> in people with type 2 diabetes: A post hoc analysis of the <scp>CONCLUDE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 332-336.	2.2	4
551	Reducing vitamin D requests in a primary care cohort: a quality improvement study. BJGP Open, 2020, 4, bjgpopen20X101090.	0.9	4
552	Diabetes: glycaemic control in type 2. Clinical Evidence, 2008, 2008, .	0.2	4
553	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. Diabetes Care, 2022, 45, 1132-1140.	4.3	4
554	Comparing Characteristics of Endometrial Cancer in Women of South Asian and White Ethnicity in England. Cancers, 2021, 13, 6123.	1.7	4
555	Relative protein intake and associations with markers of physical function in those with type 2 diabetes. Diabetic Medicine, 2022, 39, e14851.	1.2	4
556	Significant reduction in chronic kidney disease progression with sodiumâ€glucose cotransporterâ€2 inhibitors compared to dipeptidyl peptidaseâ€4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 2138-2147.	2.2	4
557	Predictors and determinants of albuminuria in people with prediabetes and diabetes based on smoking status: A cross-sectional study using the UK Biobank data. EClinicalMedicine, 2022, 51, 101544.	3.2	4
558	Approaches to the organization of multi-practice audits in primary health care in the UK. International Journal for Quality in Health Care, 1999, 11, 221-226.	0.9	3

#	Article	IF	CITATIONS
559	South Asian individuals at high risk of type 2 diabetes have lower plasma vitamin C levels than white Europeans. Journal of Nutritional Science, 2013, 2, e21.	0.7	3
560	Diabetes research in primary care: fiction, reality or essential?. Diabetic Medicine, 2018, 35, 832-834.	1.2	3
561	Individualised targets for insulin initiation in type 2 diabetes mellitus—the influence of physician and practice: a cross-sectional study in eight European countries. BMJ Open, 2019, 9, e032040.	0.8	3
562	Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. BMJ Open, 2020, 10, e034613.	0.8	3
563	Cost-effectiveness of intensive interventions compared to standard care in individuals with type 2 diabetes: A systematic review and critical appraisal of decision-analytic models. Diabetes Research and Clinical Practice, 2020, 161, 108073.	1.1	3
564	Pragmatic management of lowâ€energy diets in people with type 2 diabetes in primary care: a decision aid for clinicians. Diabetic Medicine, 2020, 37, 747-751.	1.2	3
565	Development, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal tool. Annals of Epidemiology, 2021, 55, 57-63.e15.	0.9	3
566	A cost comparison of an enhanced primary care diabetes service and standard care. Primary Care Diabetes, 2021, 15, 601-606.	0.9	3
567	De-intensification in older people with type 2 diabetes: why, when and for whom?. The Lancet Healthy Longevity, 2021, 2, e531-e532.	2.0	3
568	EXTending availability of self-management structured EducatioN programmes for people with type 2 Diabetes in low-to-middle income countries (EXTEND)—a feasibility study in Mozambique and Malawi. BMJ Open, 2021, 11, e047425.	0.8	3
569	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. Diabetes Research and Clinical Practice, 2021, 180, 108974.	1.1	3
570	No cases of asymptomatic SARS-CoV-2 infection among healthcare staff in a city under lockdown restrictions: lessons to inform â€~Operation Moonshot'. Journal of Public Health, 2020, , .	1.0	3
571	1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial. Diabetes, 2020, 69, .	0.3	3
572	Energy intake and weight during the <scp>COVID</scp> â€19 lockdown were not altered in a sample of older adults with type 2 diabetes in <scp>England</scp> . Diabetes, Obesity and Metabolism, 2022, 24, 546-549.	2.2	3
573	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. Journal of Diabetes and Its Complications, 2021, 35, 108077.	1.2	3
574	Consultation rates in people with type 2 diabetes with and without vascular complications: a retrospective analysis of 141,328 adults in England. Cardiovascular Diabetology, 2022, 21, 8.	2.7	3
575	Developing a core outcome set for patient-reported symptom monitoring to reduce hospital admissions for patients with heart failure. European Journal of Cardiovascular Nursing, 2022, 21, 830-839.	0.4	3
576	Age at diagnosis of type 2 diabetes and cardiovascular risk factor profile: A pooled analysis. World Journal of Diabetes, 2022, 13, 260-271.	1.3	3

#	Article	IF	CITATIONS
577	Measuring adherence to antihypertensive medication using an objective test in older adults attending primary care: cross-sectional study. Journal of Human Hypertension, 2022, 36, 1106-1112.	1.0	3
578	Nonâ€inferiority and clinical superiority of glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transporterâ€2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1598-1606.	2.2	3
579	Type 2 diabetes: lifetime risk of advancing from prediabetes. Lancet Diabetes and Endocrinology,the, 2016, 4, 5-6.	5.5	2
580	Variations in coronary mortality rates between English primary care trusts: observational study 1993–2010. Journal of Public Health, 2016, 38, e455-e463.	1.0	2
581	Cardiovascular risk factors and incident albuminuria in screenâ€detected type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2877.	1.7	2
582	Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Diabetes Therapy, 2017, 8, 673-682.	1.2	2
583	Let's Prevent Diabetes: from idea to implementation. Practical Diabetes, 2017, 34, 55-57.	0.1	2
584	Artificial neural networks in diabetes health care professional education: Effective Diabetes Education Now (EDEN). Practical Diabetes, 2017, 34, 268.	0.1	2
585	The impact of neighbourhood walkability on the effectiveness of a structured education programme to increase objectively measured walking. Journal of Public Health, 2018, 40, 82-89.	1.0	2
586	Screening for Diabetes and Prediabetes. Endocrinology, 2018, , 369-400.	0.1	2
587	Response to commentary by Rhew and colleagues on: Depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Annals of Medicine, 2019, 51, 99-100.	1.5	2
588	The increased risk of microvascular complications in South Asians with type 1 diabetes is influenced by migration. Diabetic Medicine, 2020, 37, 2136-2142.	1.2	2
589	Prediction of type 2 diabetes risk in people with non-diabetic hyperglycaemia: model derivation and validation using UK primary care data. BMJ Open, 2020, 10, e037937.	0.8	2
590	Effects of an Electronic Software "Prompt―With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial. Diabetes Care, 2020, 43, 1893-1901.	4.3	2
591	Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 171, 108616.	1.1	2
592	Uses and abuses of real-world data in generating evidence during a pandemic. Journal of the Royal Society of Medicine, 2021, 114, 109-110.	1.1	2
593	Clinical associations with stage B heart failure in adults with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110301.	1.4	2
594	1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes. Diabetes, 2019, 68, .	0.3	2

#	Article	IF	CITATIONS
595	420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study. Diabetes, 2019, 68, .	0.3	2
596	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS ONE, 2021, 16, e0258689.	1.1	2
597	Shared decision making in multimorbidity. , 2018, 47, 397-398.		2
598	Experience of point-of-care HbA1c testing in the English National Health Service Diabetes Prevention Programme: an observational study. BMJ Open Diabetes Research and Care, 2020, 8, .	1.2	2
599	People with diabetes and ambulance staff perceptions of a booklet-based intervention for diabetic hypoglycaemia, "Hypos can strike twice†a mixed methods process evaluation. BMC Emergency Medicine, 2022, 22, 21.	0.7	2
600	Screening for type 2 diabetes after a diagnosis of gestational diabetes by ethnicity: A retrospective cohort study. Primary Care Diabetes, 2022, 16, 445-451.	0.9	2
601	Hard to reach? Language matters when describing populations underserved by health and social care research. Public Health, 2022, 205, e28-e29.	1.4	2
602	The Effects of Omega-3 Supplementation on Depression in Adults with Cardiometabolic Disease: A Systematic Review of Randomised Control Trials. Nutrients, 2022, 14, 1827.	1.7	2
603	Risk of Diabetes Following COVID-19: Translating Evidence Into Clinical and Public Health Actions. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e4248-e4249.	1.8	2
604	Barriers to the implementation of guidelines in general practice. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 1998, 6, 7-8.	2.5	1
605	Quality of diabetes care in England: results of the Quality and Outcomes Framework for primary care. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 379-380.	0.2	1
606	Metabolic syndrome: time to weight or waist?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 302-308.	0.2	1
607	Increased physical activity is a cornerstone in the prevention of type 2 diabetes in high-risk individuals. Reply to Laaksonen DE, Lindström J, Tuomilehto J, Uusitupa M [letter]. Diabetologia, 2007, 50, 2609-2610.	2.9	1
608	All-cause mortality in relation to glycated haemoglobin in individuals with newly diagnosed type 2 diabetes: a retrospective cohort study. British Journal of Diabetes and Vascular Disease, 2013, 13, 22-30.	0.6	1
609	Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417. Diabetes Care, 2014, 37, e114-e114.	4.3	1
610	Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes. Primary Care Diabetes, 2014, 8, 119-125.	0.9	1
611	Serum Potassium and Glucose Regulation in the ADDITION-Leicester Screening Study. Journal of Diabetes Research, 2015, 2015, 1-4.	1.0	1
612	Screening for Diabetes and Prediabetes. Endocrinology, 2018, , 1-33.	0.1	1

#	Article	IF	CITATIONS
613	Polycystic ovary syndrome: An underestimated problem in primary care. International Journal of Clinical Practice, 2018, 72, e13081.	0.8	1
614	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. Canadian Journal of Cardiology, 2019, 35, 644-652.	0.8	1
615	Editorial: Studies in young adults with type 2 diabetes to inform evidence-based guidelines specifically for early-onset type 2 diabetes are urgently required. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1905-1906.	1.8	1
616	Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957. Diabetes Care, 2020, 43, e200-e201.	4.3	1
617	Toe gaps and their assessment in footwear for people with diabetes: a narrative review. Journal of Foot and Ankle Research, 2020, 13, 70.	0.7	1
618	Patientâ€reported outcomes after 10â€year followâ€up of intensive, multifactorial treatment in individuals with screenâ€detected type 2 diabetes: the ADDITIONâ€Europe trial. Diabetic Medicine, 2020, 37, 1509-1518.	1.2	1
619	Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study. Diabetes, Obesity and Metabolism, 2020, 22, 828-837.	2.2	1
620	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. BMJ Open, 2021, 11, e046912.	0.8	1
621	Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. , 2018, 20, 103.		1
622	The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e152.	0.5	1
623	Introduction: Real-World Evidence in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 29-32.	1.2	1
624	Costâ€effectiveness of professionalâ€mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GPâ€OSMOTIC trial. Diabetic Medicine, 2021, , e14747.	1.2	1
625	From the United Kingdom to Australia—Adapting a Web-Based Self-management Education Program to Support the Management of Type 2 Diabetes: Tutorial. Journal of Medical Internet Research, 2022, 24, e26339.	2.1	1
626	The effect of personal continuity of care on evidence-based management of patients with asthma in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 1998, 6, 12-13.	2.5	0
627	What is research? Views of minority groups. Journal of Epidemiology and Community Health, 2011, 65, A19-A20.	2.0	0
628	Predicting severe hypoglycaemia — a step forward. Nature Reviews Endocrinology, 2017, 13, 692-693.	4.3	0
629	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: <scp>F</scp> rom efficacy to effectiveness. Diabetes, Obesity and Metabolism, 2018, 20, 763-765.	2.2	Ο
630	Technology and chronic disease management – Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 91-92.	5.5	0

#	Article	IF	CITATIONS
631	Reply to Mantovani: "Causality between nonâ€alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes― Liver International, 2019, 39, 780-781.	1.9	0
632	Dysglycaemia and South Asian ethnicity: a proteomic discovery and confirmation analysis highlights differences in ZAG. Journal of Proteins and Proteomics, 2020, 11, 259-268.	1.0	0
633	Response to letter to the editor by Abhipsha Sur Roy and Amol Joshi regarding the article: â€`Multimorbidity and SARS-CoV-2 infection in UK Biobank' (Chudasama etÂal.). Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1281.	1.8	Ο
634	Response to: â€~Concerns about the evidence in relation to implementation of the ProFHER trial' by Handoll <i>et al</i> . BMJ Quality and Safety, 2020, 29, 432-435.	1.8	0
635	Quantifying the association between ethnicity and COVID-19 mortality: a national cohort study protocol. BMJ Open, 2021, 11, e045286.	0.8	0
636	Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States. Diabetes, Obesity and Metabolism, 2021, 23, 2251-2260.	2.2	0
637	Using observational data to prioritise COVID-19 vaccination strategies: opportunity or necessity?. Public Health, 2021, 197, e20.	1.4	Ο
638	Predictors of hypertension detection in English general practices: a cross sectional study. Journal of Public Health, 2022, 44, e1-e9.	1.0	0
639	Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records. JMIR Research Protocols, 2020, 9, e17548.	0.5	0
640	OUP accepted manuscript. Journal of Public Health, 2022, , .	1.0	0
641	Ethnic differences in the relationship between step cadence and physical function in older adults. Journal of Sports Sciences, 2022, 40, 1183-1190.	1.0	Ο
642	Cardiovascular and renal outcomes of initial combination therapy with glucoseâ€lowering agents versus a stepwise approach in newly diagnosed or treatmentâ€naÃ⁻ve type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1469-1482.	2.2	0
643	Title is missing!. , 2020, 17, e1003332.		0
644	Title is missing!. , 2020, 17, e1003332.		0
645	Title is missing!. , 2020, 17, e1003332.		0
646	Title is missing!. , 2020, 17, e1003332.		0
647	Title is missing!. , 2020, 17, e1003332.		0
648	Title is missing!. , 2020, 17, e1003332.		0

#	Article	IF	CITATIONS
649	Title is missing!. , 2020, 17, e1003332.		0
650	Title is missing!. , 2020, 17, e1003332.		0
651	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	2.2	0